These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 20723038)

  • 1. A perspective on modelling hepatitis C virus infection.
    Guedj J; Rong L; Dahari H; Perelson AS
    J Viral Hepat; 2010 Dec; 17(12):825-33. PubMed ID: 20723038
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modelling hepatitis C virus kinetics during treatment with pegylated interferon alpha-2b: errors in the estimation of viral kinetic parameters.
    Shudo E; Ribeiro RM; Perelson AS
    J Viral Hepat; 2008 May; 15(5):357-62. PubMed ID: 18380660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon.
    Herrmann E; Lee JH; Marinos G; Modi M; Zeuzem S
    Hepatology; 2003 Jun; 37(6):1351-8. PubMed ID: 12774014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential antiviral effect of PEG-interferon-alpha-2b on HIV and HCV in the treatment of HIV/HCV co-infected patients.
    Neumann A; Polis M; Rozenberg L; Jackson J; Reitano K; McLaughlin M; Koratich C; Dewar R; Masur H; Haagmans B; Kottilil S
    AIDS; 2007 Sep; 21(14):1855-65. PubMed ID: 17721093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
    Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
    Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The kinetics of hepatitis C virus infection.
    Zeuzem S
    Clin Liver Dis; 2001 Nov; 5(4):917-30. PubMed ID: 11685801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and pharmacodynamic modeling of pegylated-interferon alfa.
    Dimova RB; Talal AH
    J Hepatol; 2010 Sep; 53(3):418-20. PubMed ID: 20561707
    [No Abstract]   [Full Text] [Related]  

  • 10. Pegylated IFN-alpha2a and ribavirin in the treatment of hepatitis C.
    Aghemo A; Rumi MG; Colombo M
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):925-35. PubMed ID: 19803700
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic of Virologic Response to Pegylated Interferon and Ribavirin in Children With Chronic Hepatitis C Predicts the Effect of Treatment.
    Indolfi G; Nebbia G; Cananzi M; Maccabruni A; Zaramella M; D'Antiga L; Grisotto L; Azzari C; Resti M;
    Pediatr Infect Dis J; 2016 Dec; 35(12):1300-1303. PubMed ID: 27636721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6.
    Lukasiewicz E; Hellstrand K; Westin J; Ferrari C; Neumann AU; Pawlotsky JM; Schalm SW; Zeuzem S; Veldt BJ; Hansen BE; Verhey-Hart E; Lagging M
    Hepatology; 2007 Jan; 45(1):258-9. PubMed ID: 17187414
    [No Abstract]   [Full Text] [Related]  

  • 13. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid virological response to peginterferon and ribavirin for hepatitis C genotype 1: the role of weight-based ribavirin exposure.
    Yu ML; Dai CY; Huang JF; Chuang WL
    Hepatology; 2008 Sep; 48(3):1019-20; author reply 1020-1. PubMed ID: 18756469
    [No Abstract]   [Full Text] [Related]  

  • 16. Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.
    Breilh D; Djabarouti S; Trimoulet P; Le Bail B; Dupon M; Ragnaud JM; Fleury H; Saux MC; Thiébaut R; Chêne G; Neau D
    J Acquir Immune Defic Syndr; 2009 Nov; 52(3):428-30. PubMed ID: 19858925
    [No Abstract]   [Full Text] [Related]  

  • 17. Dynamics of hepatitis C virus infection.
    Zeuzem S; Herrmann E
    Ann Hepatol; 2002; 1(2):56-63. PubMed ID: 15115969
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis C viral kinetics during treatment with peg IFN-alpha-2b in HIV/HCV coinfected patients as a function of baseline CD4+ T-cell counts.
    Avidan NU; Goldstein D; Rozenberg L; McLaughlin M; Ferenci P; Masur H; Buti M; Fauci AS; Polis MA; Kottilil S
    J Acquir Immune Defic Syndr; 2009 Dec; 52(4):452-8. PubMed ID: 19797971
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pegylated interferons.
    Karnam US; Reddy KR
    Clin Liver Dis; 2003 Feb; 7(1):139-48. PubMed ID: 12691463
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modeling HCV kinetics under therapy using PK and PD information.
    Shudo E; Ribeiro RM; Perelson AS
    Expert Opin Drug Metab Toxicol; 2009 Mar; 5(3):321-32. PubMed ID: 19331594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.